,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
  • Forum
———Top menu
Login
 

GLOBALE DERMATOLOGIE

Globale DermatologieGlobale Dermatologie
Globale Dermatologie
Portail d'information sur la dermatologie

GLOBALE DERMATOLOGIE

  • Home
  • About
  • General informations
  • For professionnels
  • Posts in other languages
    • Allemand (Deutsch)
    • arabe (العربية)
    • chinois (中文)
    • espagnol (Español)
    • italien (Italiano)
    • japonais (日本語)
    • portugais (Português)
    • russe (русский язык)
    • tagalog
  • Find a dermatologist
  • Register
  • Contact
Menu back  
  • Home
  • About
  • General informations
  • For professionnels
  • Posts in other languages
    • back
    • Allemand (Deutsch)
    • arabe (العربية)
    • chinois (中文)
    • espagnol (Español)
    • italien (Italiano)
    • japonais (日本語)
    • portugais (Português)
    • russe (русский язык)
    • tagalog
  • Find a dermatologist
  • Register
  • Contact
 

Daily Archives: Thursday March 19th, 2015

You are here:
  1. Home
  2. 2015
  3. March
  4. 19

Psoriasis cost-effective treatments

Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in Patients with moderate to severe psoriasis (Poster) Feldman SR et al AAD 2015 Annual Meeting, San Francisco CA – United States With the injected biologics treatment for psoriasis and the newer oral “small molecules” for the treatment of psoriasis the authors found it useful…

Thursday March 19th, 2015Leave a commentNotes de congrès/conférencesBy ofredon@oxicat.com

Psoriasis: An Effective Oral Treatment

Introduction The drug is called apremilast under the brand name Otezla It is indicated in patients with moderate-to-severe plaque psoriasis Studied since 2004 in clinical trials in over 3500 patients Is it effective ? In a randomized-control trial 1257 with moderate-to-severe psoriasis and evaluated after 16 weeks (after a week of progressively increasing dosage) The…

Thursday March 19th, 2015Notes de congrès/conférencesBy ofredon@oxicat.com
© Globale Dermatologie 2015 - Tous droits réservés